Incorporation of anti-angiogenesis therapy in the management of advanced ovarian carcinoma—Mechanistics, review of phase III randomized clinical trials, and regulatory implications-Reference-Cited by-同舟云学术

Incorporation of anti-angiogenesis therapy in the management of advanced ovarian carcinoma—Mechanistics, review of phase III randomized clinical trials, and regulatory implications

Published:2014-02 Issue:2 Volume:132 Page:496-505
ISSN:0090-8258
Container-title:Gynecologic Oncology
language:en
Short-container-title:Gynecologic Oncology

Author:

Eskander Ramez N.,Tewari Krishnansu S.

Publisher

Elsevier BV

Subject

Obstetrics and Gynaecology,Oncology

Reference70 articles.

1. Cancer statistics, 2013;Siegel;CA Cancer J Clin,2013

2. Trials with impact on clinical management: first line;Bookman;Int J Gynecol Cancer,2009

3. Activity of bevacizumab (rhuMAB VEGF) in advanced refractory epithelial ovarian cancer;Monk;Gynecol Oncol,2005

4. Platinum-sensitive recurrence in ovarian cancer: the role of tumor microenvironment;Chien;Front Oncol,2013

5. Molecular mechanisms of cisplatin resistance;Galluzzi;Oncogene,2012

Cited by 94 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Ag(I)-NHC/TBHP promoted aqueous synthesis of some new quinoline-aromatic amides; Anti-proliferative, Anti-VEGFR-2 and Molecular docking studies;Journal of Molecular Structure;2024-10

2. SEfficacy and safety of apatinib in the treatment of patients with platinum‑resistant ovarian cancer: A systematic review and network meta‑analysis;Experimental and Therapeutic Medicine;2024-07-26

3. New thiazolidine-2,4-diones as potential anticancer agents and apoptotic inducers targeting VEGFR-2 kinase: Design, synthesis, in silico and in vitro studies;Biochimica et Biophysica Acta (BBA) - General Subjects;2024-06

4. Design and In Silico and In Vitro Evaluations of a Novel Nicotinamide Derivative as a VEGFR-2 Inhibitor;Journal of Chemistry;2024-03-01

5. Discovery of new thiazolidine-2,4-dione derivatives as potential VEGFR-2 inhibitors: In vitro and in silico studies;Heliyon;2024-01